Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TYRA
- Price
- 7.96
- Stock movement up
- +0.41 (5.43%)
- Company name
- Tyra Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 402.80M
- Ent value
- 317.21M
- Price/Sales
- 802.39
- Price/Book
- 1.11
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -48.11%
- 3 year return
- -8.88%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TYRA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 802.39 |
| Price to Book | 1.11 |
| EV to Sales | 631.90 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.60M |
| EPS (TTM) | -1.42 |
| FCF per share (TTM) | -1.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 502.00K |
| Gross profit (TTM) | 152.00K |
| Operating income (TTM) | -100.09M |
| Net income (TTM) | -83.74M |
| EPS (TTM) | -1.42 |
| EPS (1y forward) | -1.94 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 30.28% |
| Operating margin (TTM) | -19938.65% |
| Profit margin (TTM) | -16681.27% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 103.89M |
| Net receivables | 0.00 |
| Total current assets | 365.61M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 380.59M |
| Accounts payable | 1.17M |
| Short/Current long term debt | 6.32M |
| Total current liabilities | 12.37M |
| Total liabilities | 18.30M |
| Shareholder's equity | 362.29M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -63.72M |
| Capital expenditures (TTM) | 1.26M |
| Free cash flow (TTM) | -64.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -23.11% |
| Return on Assets | -22.00% |
| Return on Invested Capital | -23.09% |
| Cash Return on Invested Capital | -17.92% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.62 |
| Daily high | 8.02 |
| Daily low | 7.52 |
| Daily Volume | 217K |
| All-time high | 31.35 |
| 1y analyst estimate | 31.00 |
| Beta | 1.08 |
| EPS (TTM) | -1.42 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 29 May 2025 |
Downside potential
Loading...
Downside potential data
| TYRA | S&P500 | |
| Current price drop from All-time high | -74.61% | -12.89% |
| Highest price drop | -83.22% | -56.47% |
| Date of highest drop | 17 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -54.30% | -11.07% |
| Avg time to new high | 112 days | 12 days |
| Max time to new high | 862 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
402.80M
Marketcap category
Small-cap
Description
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Employees
49
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page